Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials

Table 2 Sensitivity analysis of the effects of ramosetron vs placebo in irritable bowel syndrome with diarrhea

	Study removed	Ramosetron		Placebo		Pooled relative risks(RRs) with 95% confidence interval(CI)
	Study removed	Events	Total	Events	Total	Pooled relative risks(RRs) with 95% confidence interval(CI)
Relief of overall IBS symptoms	None	372	803	216	801	1.70 [1.48, 1.95]
	Matsueda K 2008a [25]	249	540	145	536	1.70 [1.40, 2.06]
	Matsueda K 2008b [26]	329	702	188	697	1.73 [1.47, 2.03]
	Fukudo S 2014 [22]	314	656	190	653	1.64 [1.42, 1.89]
	Fukudo S 2015 [23]	224	511	125	517	1.80 [1.50, 2.15]
Relief of abdominal discomfort/pain	None	368	803	259	801	1.41 [1.24, 1.59]
	Matsueda K 2008a [25]	248	540	171	536	1.43 [1.22, 1.66]
	Matsueda K 2008b [26]	330	702	232	697	1.40 [1.23, 1.60]
	Fukudo S 2014 [22]	308	656	222	653	1.38 [1.20, 1.57]
	Fukudo S 2015 [23]	218	511	152	517	1.44 [1.22, 1.71]
Improvement in abnormal bowel habits	None	358	803	205	801	1.72 [1.50, 1.98]
	Matsueda K 2008a [25]	243	540	142	536	1.69 [1.38, 2.06]
	Matsueda K 2008b [26]	314	702	174	697	1.77 [1.52, 2.06]
	Fukudo S 2014 [22]	306	656	182	653	1.66 [1.44, 1.93]
	Fukudo S 2015 [23]	211	511	117	517	1.80 [1.46, 2.23]
Improvement in stool consistency	None	184	439	106	432	1.71 [1.40, 2.08]
	Fukudo S 2014 [22]	119	292	69	284	1.68 [1.31, 2.15]
	Fukudo S 2015 [23]	65	147	37	148	1.77 [1.27, 2.47]

ISSN: 1471-230X